SCHEMBL7330835

SCHEMBL7330835

COc1ccc(Br)cc1-c1ncc(CO)[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.51
DRD4 P21917 1/20 0.51
DRD3 P35462 1/20 0.51
AMY1A P0DUB6 2/20 0.46
MC4R P32245 3/20 0.46
GRK6 P43250 1/20 0.45
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
PPARG P37231 1/20 0.40
GFER P55789 1/20 0.40
NCOA2 Q15596 1/20 0.40
NCOA1 Q15788 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
POLB P06746 1/20 0.40
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14507262 0.84 DRD2 (0.47) DRD2DRD4DRD3AMY1AMC4R
SCHEMBL6859787 0.73 AMY1A (0.49) DRD2DRD4DRD3AMY1AGRK6
SCHEMBL12714762 0.70 ALDH1A1 (0.50) ALDH1A1MAPTPOLBMEN1MAPK1
SCHEMBL12284103 0.70 FFAR1 (0.46) AMY1AGRK6
SCHEMBL14125145 0.70 GAA (0.56) AMY1AGRK6MGAMGAASI
SCHEMBL18512282 0.67 AMY1A (0.48) DRD2DRD4DRD3AMY1AGRK6
SCHEMBL14266638 0.67 CBFB (0.58) LMNAPOLBSMN1; SMN2
SCHEMBL28895392 0.66 GAA (0.53) MGAMGAASIMGAM2ALDH1A1
SCHEMBL10206881 0.66 AMY1A (0.56) AMY1AGRK6MAPTMEN1KMT2A
SCHEMBL31277617 0.66 POLB (0.49) GRK6MGAMGAASIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5681956-A USEFUL IN DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA AND DEPRESSION AS WELL AS PARKINSONISM NEUROGEN CORPORATION (US) 1997-10-28 US disclosed
EP-0783494-A1 CERTAIN AMINOMETHYL PHENYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1997-07-16 EP disclosed
US-5646279-A USEFUL IN THE DIAGNOSIS AND TREATMENT OF AFFECTIVE DISORDERS, MOVEMENT DISORDERS AND SIDE EFFECTS ASSOCIATED WITH NEUROLEPTIC AGENTS NEUROGEN CORPORATION (US) 1997-07-08 US disclosed
US-5646280-A FOR TREATING SCHIZOPHRENIA, DEPRESSION, PARKINSON*S DISEASE AND THE SIDE EFFECTS OF NEUROLEPTIC AGENTS NEUROGEN CORPORATION (US) 1997-07-08 US disclosed
US-5633376-A Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands NEUROGEN CORPORATION (US) 1997-05-27 US disclosed
WO-1996010018-A1 CERTAIN AMINOMETHYL PHENYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1996-04-04 WO disclosed
US-5428164-A Useful for treating and diagnosis of schizophrenia and depression as well as parkinson's disease NEUROGEN CORPORATION (US) 1995-06-27 US disclosed
EP-0640075-A1 CERTAIN AMINOMETHYL PHENYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1995-03-01 EP disclosed
US-5159083-A Treatment of schizophrenia, depression, parkinson's disease; side effect reduction NEUROGEN CORPORATION (US) 1992-10-27 US disclosed
WO-1992012134-A2 CERTAIN AMINOMETHYL PHENYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1992-07-23 WO disclosed